Company profilePharmaceutical#118 of 1,318 in Pakistan✓ No DRAP alerts

CCL Pharmaceuticals (Pvt.) Ltd. DML: 000052

Pharmaceutical company · 138 brands · 196 molecules

Ranked #22 of 137 companies in Anti-Infectives

138 registered products 57 pharmaceutical brands 196 distinct molecules 0 DRAP alerts

Company overview

138
registered products
57
pharmaceutical brands
196
distinct molecules
12
therapeutic classes
0
DRAP alerts

CCL Pharmaceuticals (Pvt.) Ltd. DML: 000052 is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 138 product registrations across 196 distinct molecules. It is the 118th largest registrant in Pakistan by product count, and ranks 22nd of 137 in Anti-Infectives. Its portfolio is concentrated in Anti-Infectives and Cardiac Care. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by CCL

66 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Anti-Infectives 1

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

47
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202647

Top molecules by brand count

Thiamine6 brands
Pyridoxine6 brands
Metformin5 brands
Isoniazid5 brands
Rifampicin5 brands
Riboflavin5 brands
Valsartan4 brands
Ethambutol4 brands

Therapeutic classes

Anti-Infectives · 6Cardiac Care · 5Antineoplastics · 5Neuro · 5Gastro · 3Antiepileptics · 3Pain Management · 3Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 2Lipid Modifying Agents · 2Angiotensin-Ii Antagonists, Combinations · 2Quinolone Antibacterials · 2Diabetes · 2

Conditions treated

General Infections · 4Ulcer/Reflux/Flatulence/Acidity · 2High Cholestrol · 2Anxiety/Depression/Insomnia · 2Hypertension · 2Oral Agents · 2Arthritis · 2Heart Failure · 1Malaria · 1Epilepsy/Convulsion · 1Weight Loss · 1Muscle Relaxant/Spasm · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official42 products · Rs 54.27 – Rs 31,598.91
DVAGO28 products · Rs 56.11 – Rs 1,942.7
Servaid66 products · Rs 38.6 – Rs 2,900
Median across source: Rs 460.06

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Wilshire Laboratories (Private) Limited holds 123 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmlodipineAmoxicillinAmoxycillin
Atco Pharma International (Pvt) Ltd holds 214 molecules not in this portfolio
Acetylsalicylic AcidAcyclovirAdapaleneAdapleneAlbuterolAminophylline
HELIX PHARMA (PRIVATE) LIMITED holds 106 molecules not in this portfolio
000 I.UAmlodipineAmylaseArtemetherArtesunateAscorbic Acid

Get the full profile for CCL

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.